AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: AZD2281
Drug: matching placebo

First Posted Date: 2008-09-16

Last Posted Date: 2024-03-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 265

Registration Number: NCT00753545

Locations: 🇬🇧
Research Site, Wirral, United Kingdom

To Evaluate the Effect of Food on the Pharmacokinetics (PK) of AZD0328

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: AZD0328

First Posted Date: 2008-09-15

Last Posted Date: 2008-10-29

Lead Sponsor: AstraZeneca

Target Recruit Count: 14

Registration Number: NCT00752830

Locations: 🇸🇪
Research Site, Lund, Sweden

A Sedation/Cognition/EEG Study Using AZD6280 and Comparator

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: AZD6280
Drug: Placebo
Drug: Lorazepam

First Posted Date: 2008-09-11

Last Posted Date: 2009-06-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 17

Registration Number: NCT00750802

Locations: 🇳🇱
Research Site, Leiden, Netherlands

Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

Phase 1

Active, not recruiting

Conditions: Solid Tumors

Interventions: Drug: cediranib

First Posted Date: 2008-09-11

Last Posted Date: 2024-10-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 64

Registration Number: NCT00750841

Locations: 🇬🇧
Research Site, London, United Kingdom

Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: cediranib (RECENTIN TM, AZD2171)

First Posted Date: 2008-09-10

Last Posted Date: 2011-03-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 46

Registration Number: NCT00750425

Locations: 🇩🇰
Research Site, Kobenhavn, Denmark

Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With Schizophrenia

Completed

Conditions: Schizophrenia
Schizoaffective Disorder
Schizophreniform Disorder

First Posted Date: 2008-09-10

Last Posted Date: 2010-12-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 100

Registration Number: NCT00749970

Locations: 🇪🇸
Research site, Tarragona, Spain
🇪🇸
Research Site, Zaragoza, Spain

Non-interventional Study -Observe Treatment Efficacy in Maintaining Symptoms Control in Schizophrenia With Seroquel XR

Completed

Conditions: Schizophrenia

First Posted Date: 2008-09-10

Last Posted Date: 2010-02-05

Lead Sponsor: AstraZeneca

Target Recruit Count: 578

Registration Number: NCT00750087

Locations: 🇷🇴
Research Site, Zalau, Romania

Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses of AZD8566.

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: AZD8566
Drug: Placebo

First Posted Date: 2008-09-09

Last Posted Date: 2009-04-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 108

Registration Number: NCT00749333

Locations: 🇬🇧
Research Site, Nottingham, United Kingdom

DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: Recentin (Cediranib)

First Posted Date: 2008-09-09

Last Posted Date: 2011-07-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 35

Registration Number: NCT00748891

Locations: 🇬🇧
Research Site, London, United Kingdom

Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction

Phase 2

Completed

Conditions: Left Ventricle Function

Interventions: Drug: AZD1305
Drug: Placebo

First Posted Date: 2008-09-09

Last Posted Date: 2011-06-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 16

Registration Number: NCT00748982

Locations: 🇸🇪
Research Site, Goteborg, Sweden

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy